Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Statins Slow the Progression of Advanced MS in Clinical Trial

Published: Saturday, March 29, 2014
Last Updated: Saturday, March 29, 2014
Bookmark and Share
The work is published in the Lancet.

Statins may provide doctors with an unlikely new weapon with which to slow the progression of multiple sclerosis (MS).

No treatments can currently abate the advanced stage of the disease, known as secondary progressive MS, which gradually causes patients to become more disabled.

In a two-year clinical trial involving 140 patients with secondary progressive MS, the drug simvastatin slowed brain shrinkage, which is thought to contribute to patients' impairments. Supporting this finding, patients on simvastatin achieved better scores on movement tests and questionnaires that assess disability than patients taking a placebo.

MS is a neurological condition that affects around 2.3 million people worldwide. Most patients are initially diagnosed with relapsing-remitting MS, which causes periodic attacks. Around 65 per cent of people with relapsing remitting MS develop secondary progressive MS within 15 years of being diagnosed. The secondary progressive phase is where MS has the most personal and societal costs.

The authors of the new study, which was led by Imperial College London, said the findings were very encouraging, but would need to be replicated in a larger trial.

"At the moment, we don't have anything that can stop patients from becoming more disabled once MS reaches the progressive phase," said Dr Richard Nicholas, co-author of the study from the Department of Medicine at Imperial. "Discovering that statins can help slow that deterioration is quite a surprise. This is a promising finding, particularly as statins are already cheap and widely used.

"We need to do a bigger study with more patients, possibly starting in the earlier phase of the disease, to fully establish how effective it is," he added.

Dr Nicholas ran the trial with Dr Jeremy Chataway, then in the Department of Medicine at Imperial and now at University College London.

Statins are taken by millions of people to lower cholesterol and prevent heart disease, but it's unclear why they would have a beneficial effect on MS.

Some small studies have found a small benefit from statins in relapsing remitting MS, which is more treatable.

Secondary progressive MS has proven more challenging to alleviate. In 2013, cannabis became the latest drug to prove unsuccessful at slowing the progression of MS in a clinical trial.

This clinical trial is the culmination of long-standing research led by Professor John Greenwood at the UCL Institute of Ophthalmology showing the potential therapeutic benefits of using statins to treat autoimmune diseases such as multiple sclerosis and uveitis.

Professor Greenwood said, "After nearly two decades of research, it is immensely gratifying to see this work progress into the clinic to deliver benefits to patients."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gene Therapy for Cystic Fibrosis Shows Encouraging Trial Results
A therapy that replaces the faulty gene responsible for cystic fibrosis in patients' lungs has produced encouraging results in a major UK trial.
Friday, July 03, 2015
Alcoholic Hepatitis Treatments Fail to Keep Patients Alive
The study is published in the New England Journal of Medicine.
Friday, May 01, 2015
Study Finds Potential New Target to Treat Asthma Attacks Brought on by Colds
Results suggest that IL-25 could be a target for possible treatments to prevent asthma attacks.
Tuesday, October 07, 2014
First Gene Therapy Trial Launched for Heart Patients with Mechanical Pumps
Patient received new gene therapy at Harefield Hospital, London.
Tuesday, August 12, 2014
Stem Cells Show Promise for Stroke in Pilot Study
Findings are published in the journal Stem Cells Translational Medicine.
Saturday, August 09, 2014
Statins Slow the Progression of Advanced MS in Clinical Trial
The work is published in the Lancet.
Friday, March 21, 2014
New Drug Treatment Reduces Chronic Pain Following Shingles
New drug EMA401 reduce pain and did not cause any serious side effects.
Friday, February 07, 2014
Malaria Drug Target Raises Hopes for New Treatments
Scientists identify way to stop malaria parasites from multiplying.
Thursday, December 26, 2013
Badgers Ultimately Responsible for Around Half of TB in Cattle, Study Estimates
The findings are published in the journal PLOS Currents: Outbreaks.
Tuesday, November 05, 2013
Multi-drug Pills Help People Stick to Heart Disease Prevention Regimens
Findings are published in the Journal of the American Medical Association.
Friday, September 27, 2013
£73m Powerhouse of Biomedical Research Opens at Imperial College London
Designed to expand and accelerate the translation of scientific discoveries.
Wednesday, November 21, 2012
Cystic Fibrosis Gene Therapy Programme Gets Green Light with Public Funding
Gene therapy trial for CF to begin in March.
Friday, March 16, 2012
One-a-day Heart Polypill to be Tested in new International Trial
Researchers to explore whether a new, low cost, one-a-day combined 'polypill' could reduce the risk of heart attacks and related problems.
Monday, May 17, 2010
University Research Contributes £45 Billion a Year to the UK Economy, According to new Impact Study
A new economic impact assessment of university research suggests that the £3.5 billion a year currently spent on publicly funded research generates an additional annual output of £45 billion in UK companies.
Monday, March 15, 2010
HIV Vaccine Failure Probably Caused By Virus Used, Says New Research
Researchers say, failure was probably caused by the immune system reacting to the virus 'shell' used to transmit the therapy around the body.
Tuesday, November 17, 2009
Scientific News
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!